UCB Cimzia BLA Submission Could Provide First Subcutaneous Injection For Crohn’s
This article was originally published in The Pink Sheet Daily
Executive Summary
Requested priority review could result in approval by early September for competitor to J&J’s Remicade and AstraZeneca’s Entocort EC.
You may also be interested in...
UCB Receives “Complete Response” Letter For Cimzia
Firm says FDA seeks new information and clarification regarding the BLA.
UCB Receives “Complete Response” Letter For Cimzia
Firm says FDA seeks new information and clarification regarding the BLA.
Abbott Anticipates Humira sBLA For Crohn’s Disease By Year-End
Application would be buoyed by new Phase III remission data.